Dare Bioscience (DARE) Q2 FY26 earnings call

Dare Bioscience is transitioning into a commercial-stage company, with its first product, Flora Sync LF5, launched and DARE to PLAY Sildenafil Cream nearing prescription dispensing. The company is executing a dual path strategy, leveraging 503B compounding for early market entry while pursuing FDA approvals, and building a scalable commercial platform via the DARE Health Hub. This quarter marks a pivotal shift from a science-driven development focus to active commercial execution in women's health.